Quantum BioPharma Advances Neurological and Wellness Pipeline Amid Rising Global Burden of Neurological Disorders

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is building a diversified pipeline targeting neurological and wellness markets, as the global burden of neurological diseases continues to rise. The company's flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for multiple sclerosis (MS). According to the World Health Organization, neurological conditions are now the leading cause of illness and disability worldwide, affecting over one-third of the global population. Many current therapies for neurodegenerative diseases focus on symptom management rather than addressing underlying neurodegeneration, leaving substantial unmet medical needs. For MS, current drugs do not address loss of mobility and function, a persistent unmet patient need.

In addition to its MS program, Quantum BioPharma has expanded into the consumer wellness space with unbuzzd™, an innovative, clinically validated alcohol metabolism accelerator designed to help individuals sober up faster. This product targets the growing market for alcohol health and sobriety, offering a scientifically backed solution for responsible drinking.

Quantum BioPharma's dual focus on neurological therapeutics and consumer health reflects a strategic approach to address both critical medical conditions and everyday wellness challenges. The company's pipeline highlights its commitment to innovation in areas where existing treatments are inadequate. For more information on the latest news and updates regarding QNTM, visit the company's newsroom at https://nnw.fm/QNTM.

NetworkNewsWire (NNW) is a specialized communications platform focusing on financial news and content distribution for private and public companies and the investment community. It is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With a seasoned team of contributing journalists and writers, NNW brings its clients unparalleled recognition and brand awareness.

For more information, please visit https://www.NetworkNewsWire.com. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.